Dr.Vidhyadhar, A20261
This is a prospective,randomized,comparative study to determine whether Ologen implantation is a safe and effective alternative to subconjunctival mitomycin C for primary angle closure glaucoma with cataract. Patients were randomized into two groups (22 patients in each). Group A received Ologen while group B received mitomycin C. The mean age in groups A and B were 61.55 ± 9.32 years and 66.59 ± 9.7 years.Group A had complete success of 77.2% & qualified success in 18.2%.Group B had complete success in 54.6% & 36.3% of qualified success.These success rates being assessed at 6months were not statistically significant.Flat belb being the most common complication and laser suturolysis being the most common intervention required in either group.We conclude that the Ologen is equally safe, and effective alternative to subconjunctival injection of Mitomycin C for improving the success rate of Phacotrabeculectomy and may avoid the side effects associated with the use of MMC.
Leave a Comment